Novel Cell-Squeezing Microfluidic Platform Revolutionizes Breast Cancer Risk Assessment

April 24, 2026 - 09:21

Researchers at City of Hope, a leading cancer research and treatment organization, in collaboration with scientists from the University of California, Berkeley, have unveiled a groundbreaking microfluidic platform that could transform how breast cancer risk is evaluated at the cellular level. This innovative technology, known as cell squeezing, offers a more precise and personalized approach to assessing a woman's likelihood of developing breast cancer.

The microfluidic device works by gently squeezing individual cells through narrow channels, forcing them to deform. By analyzing how cells respond to this mechanical stress, researchers can detect subtle changes in cellular behavior that may indicate an elevated risk of cancer. Unlike traditional risk assessment methods, which rely on factors such as family history, genetic mutations, or mammographic density, this platform provides direct insight into the physical properties of cells, offering a functional readout of cancer susceptibility.

The development holds significant promise for early detection and prevention. By identifying high-risk individuals earlier, clinicians could implement more tailored screening schedules or preventive interventions. The platform is also minimally invasive, requiring only a small sample of cells from a routine biopsy or blood draw. While still in the research phase, the team believes this technology could eventually become a standard tool in women's health clinics, empowering patients and doctors with actionable cellular-level data. Further studies are underway to validate the platform across diverse populations and refine its accuracy for clinical use.